Rosario Campelo-Garcia

Santiago De Compostela, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 97 publications

Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1.

Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1.

Journal: International journal of molecular sciences

Published: June 12, 2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.

Journal: Expert opinion on biological therapy

Published: May 20, 2026

Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study.

Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study.

Journal: Clinical lung cancer

Published: April 07, 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 20, 2026

Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence.

Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 17, 2026

Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment.

Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment.

Journal: Journal for immunotherapy of cancer

Published: January 23, 2026

Clinical Characteristics and Survival Outcomes in Patients With Small Cell Lung Cancer in Spain: An Analysis of the Thoracic Tumor Registry (2016-2025).

Clinical Characteristics and Survival Outcomes in Patients With Small Cell Lung Cancer in Spain: An Analysis of the Thoracic Tumor Registry (2016-2025).

Journal: Archivos de bronconeumologia

Published: January 13, 2026

Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.

Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.

Journal: Frontiers in artificial intelligence

Published: December 12, 2025

Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 01, 2025

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 07, 2025

Interpreting immunogenicity in oncology clinical trials.

Interpreting immunogenicity in oncology clinical trials.

Journal: Cancer treatment reviews

Published: June 12, 2025

Showing 1-12 of 97

Last Updated: 09/26/2026